Management team

Chief Executive Officer & Co-Chairman of the Board

Professor Semechkin is a specialist in system analysis, strategic planning and corporate management. He is a member of the Russian Academy of Sciences and has been Deputy Director of Institute of System Analysis since 2004. Professor Semechkin was awarded the Russian Government Award in Science and Technology in 2006 and has written several scientific books. He has over 20 years of experience creating and managing businesses across different industries and scientific sectors.

Executive Vice President, Chief Scientific Officer & Principal Financial Officer
Chief Executive Officer, Lifeline Skin Care

Dr. Kern was trained in medical genetics, embryology and stem cell biology. He holds a Ph.D. degree in Human Physiology from the Russian Academy of Medical Sciences and has broad expertise in neuroscience, and was part of the team, along with scientists from the NYU Medical School that elucidated the physiological changes that occur in the brains of Parkinson’s disease patients. Dr. Kern directs ISCO’s R&D programs including stem cell derivation, differentiation and the pre-clinical and clinical evaluation of stem cell derived cells and tissue. He has developed a general method of deriving highly pure populations of neural stem cells and dopaminergic neurons from pluripotent stems cells that is novel, practical and suitable for use in a clinical setting. Dr. Kern is a well-known speaker on stem cell biology, including the use of stem cells for neurology and skin regeneration. He has more than 40 publications in the field of Parkinson’s disease and stem cell biology and he is an active member of the American Academy of Neurology.

President, Lifeline Cell Technology

Ms. McGee has been with the company since 2006 and currently leads our subsidiary, Lifeline Cell Technology (LCT). During her tenure at LCT she has developed and/or managed the tech transfer of nearly all the products in LCT’s catalog. She progressed from product development to managing the manufacturing department and eventually the entire facility in Maryland. Prior to joining LCT, she had roles at BioIVT (formerly InVitro Technologies), PerkinElmer (through acquisition of Receptor Biology, Inc.), and Oceanix Biosciences Corporation honing her skills and knowledge of cell culture, primary cell isolation, assay development, in vitro pharmacology and ADME-TOX. She has contributed to several posters and papers on a wide variety of topics such as the use of aequorin for functional screening of G-protein coupled receptors, use of renal cortical cells as a model for toxicity and transport studies, cross-species comparison of hepatocyte cytochrome P450 levels, and arctic ground squirrel neural stem cells as a tool for in vitro studies of ischemia to model stroke.

Ms. McGee received her MBA from University of MD Global Campus and earned her bachelor’s in biology from Loyola University in MD and has extensive postgraduate coursework in pharmacology and immunology from University of MD at Baltimore and Hood College.